Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is trying to find out if a medicine called Blenrep can keep multiple myeloma from coming back after a patient has had a certain kind of transplant. The study is also going to make sure it's safe to use Blenrep after the transplant.
This study is trying to find out if a medicine called Blenrep can keep multiple myeloma from coming back after a patient has had a certain kind of transplant. The study is also going to make sure it's safe to use Blenrep after the transplant.
*Third Opinion AI Generated Synopsis
Trial Summary
The goal of this clinical research study is to learn if belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT). The safety of this drug after transplant will also be studied
The goal of this clinical research study is to learn if belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT). The safety of this drug after transplant will also be studied
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: